Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020221209 - CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Publication Number WO/2020/221209
Publication Date 05.11.2020
International Application No. PCT/CN2020/087259
International Filing Date 27.04.2020
IPC
C07H 19/16 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
16Purine radicals
C07H 19/20 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
16Purine radicals
20with the saccharide radical being esterified by phosphoric or polyphosphoric acids
C07H 19/207 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
16Purine radicals
20with the saccharide radical being esterified by phosphoric or polyphosphoric acids
207the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine-adenine dinucleotide or nicotinamide-adenine dinucleotide
A61K 31/70 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
A61K 31/7052 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K 31/7076 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
Applicants
  • 上海和誉生物医药科技有限公司 ABBISKO THERAPEUTICS CO., LTD. [CN]/[CN]
Inventors
  • 邓海兵 DENG, Haibing
  • 喻红平 YU, Hongping
  • 陈椎 CHEN, Zhui
  • 徐耀昌 XU, Yaochang
Agents
  • 上海一平知识产权代理有限公司 XU & PARTNERS, LLC.
Priority Data
201910350348.628.04.2019CN
201910510367.013.06.2019CN
201911375322.327.12.2019CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
(FR) INHIBITEUR DE CD73, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
(ZH) 一种CD73抑制剂,其制备方法和应用
Abstract
(EN)
A CD73 inhibitor having the structure represented by formula (I), a preparation method therefor and an application thereof. The series of compounds can be widely applied in the preparation of drugs for treating cancers or tumors that are at least partially mediated by CD73, autoimmune diseases and disorders, and metabolic diseases, in particular drugs for treating melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumor, lymphoma, ovarian cancer, and Kaposi's sarcoma. A new generation of CD73 inhibitor drugs is expected to be developed.
(FR)
L'invention concerne un inhibiteur de CD73 ayant une structure représentée par la formule (I), son procédé de préparation et son utilisation. La série de composés peut être largement utilisée dans la préparation de médicaments destinés au traitement de cancers ou de tumeurs qui sont au moins partiellement induits par CD73, de maladies et de troubles auto-immuns, et de maladies métaboliques, en particulier des médicaments pour le traitement du mélanome, du cancer du côlon, du cancer du pancréas, du cancer du sein, du cancer de la prostate, du cancer du poumon, de la leucémie, d'une tumeur du cerveau, du lymphome, du cancer de l'ovaire et du sarcome de Kaposi. La présente invention permet de développer une nouvelle génération de médicaments inhibiteurs de CD73.
(ZH)
一种具有式(I)结构的CD73抑制剂,其制备方法和应用。系列化合物可广泛应用于制备治疗至少部分由CD73介导的癌症或肿瘤、自身免疫性疾病及紊乱、代谢性疾病的药物,特别是治疗黑色素瘤、结肠癌、胰腺癌、乳腺癌、前列腺癌、肺癌、白血病、脑瘤、淋巴瘤、卵巢癌和卡波西氏肉瘤的药物,有望开发成新一代CD73抑制剂药物。
Latest bibliographic data on file with the International Bureau